MX2009009700A - Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso. - Google Patents

Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.

Info

Publication number
MX2009009700A
MX2009009700A MX2009009700A MX2009009700A MX2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A
Authority
MX
Mexico
Prior art keywords
chemotherapy
hla class
remedy
active ingredient
diabody
Prior art date
Application number
MX2009009700A
Other languages
English (en)
Inventor
Toshio Matsumoto
Shuji Ozaki
Masahiro Abe
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39759531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2009009700A publication Critical patent/MX2009009700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se ha aclarado que la actividad citotóxica del diacuerpo C3B3 es inducida con menor concentración en líneas celulares de tumor hematológico resistentes a agentes quimioterapéuticos que sobreexpresan proteínas MDR1 y HLA clase lA, que en la cepa originaria. También se halló que cuando la línea celular de tumor hematológico resistente a agentes quimioterapéuticos se trata previamente con un diacuerpo C3B3, la actividad citotóxica del fármaco quimioterapéutico solo aumenta y el fármaco es incorporado en una mayor cantidad en las células. Más específicamente, se descubrió que el diacuerpo C3B3 ejerce una actividad antitumoral sobre las células tumorales que expresan MDR1 que sobreexpresan HLA de clase I, y tiene un efecto para superar la resistencia al fármaco.
MX2009009700A 2007-03-12 2008-03-12 Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso. MX2009009700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007062339 2007-03-12
PCT/JP2008/054443 WO2008111597A1 (ja) 2007-03-12 2008-03-12 Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用

Publications (1)

Publication Number Publication Date
MX2009009700A true MX2009009700A (es) 2009-10-07

Family

ID=39759531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009700A MX2009009700A (es) 2007-03-12 2008-03-12 Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.

Country Status (15)

Country Link
US (1) US20100092461A1 (es)
EP (1) EP2133093A1 (es)
JP (1) JPWO2008111597A1 (es)
KR (1) KR20090119992A (es)
CN (1) CN101687034A (es)
AR (1) AR066690A1 (es)
AU (1) AU2008225478A1 (es)
BR (1) BRPI0808731A2 (es)
CA (1) CA2680280A1 (es)
CL (1) CL2008000719A1 (es)
IL (1) IL200375A0 (es)
MX (1) MX2009009700A (es)
PE (1) PE20081881A1 (es)
TW (1) TW200846372A (es)
WO (1) WO2008111597A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033499A1 (ja) * 2002-10-11 2004-04-22 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
AU2004297109A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
EP1757686A4 (en) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd INDUCER OF CELL DEATH
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
CN101262885B (zh) * 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
PE20081004A1 (es) * 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
PL2802607T3 (pl) 2012-01-13 2018-03-30 Julius-Maximilians-Universität Würzburg Dwuskładnikowa komplementacja funkcjonalna wywoływana przez podwójny antygen
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
US20230066830A1 (en) * 2019-12-20 2023-03-02 Virginia Commonwealth University Methods and compositions for inducing apoptosis in cancer stem cells

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5077216A (en) * 1988-07-06 1991-12-31 The Trustees Of Dartmouth College Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5223241A (en) * 1990-10-01 1993-06-29 The General Hospital Corporation Method for early detection of allograft rejection
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5837821A (en) * 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CA2117477C (en) * 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
ATE280835T1 (de) * 1993-09-03 2004-11-15 Chugai Pharmaceutical Co Ltd Apoptose induzierender monoklonaler antikörper
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
IL114909A (en) * 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
DK0812136T3 (da) * 1995-02-28 2001-02-19 Procter & Gamble Fremgangsmåde til fremstilling af ikke-kulsyreholdige læskedrikke med bedre mikrobiel stabilitet
EP0817794A1 (en) 1995-03-31 1998-01-14 Jakob Bohr Method for protein folding
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
WO1997000271A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
FR2745008A1 (fr) * 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
US6579692B1 (en) * 1996-03-06 2003-06-17 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
DE69735202T2 (de) * 1996-05-09 2006-11-02 Pharma Pacific Pty. Ltd., Brighton-Le-Sands Stimulierung wirtseigener abwehrmechanismen gegen krebs
US6323000B2 (en) * 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
PL339265A1 (en) * 1997-09-11 2000-12-04 Chugai Pharmaceutical Co Ltd Apoptose causing monoclonal antibody
US5998593A (en) * 1998-03-10 1999-12-07 Abbott Laboratories Fluorescent enzyme substrates
US7081360B2 (en) * 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
AU2001288061A1 (en) * 2000-10-03 2002-04-15 Banyu Pharmaceutical Co., Ltd. Drug resistance-associated gene and use thereof
JPWO2002033072A1 (ja) * 2000-10-20 2004-02-26 中外製薬株式会社 低分子化ｔｐｏアゴニスト抗体
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
CA2444098C (en) * 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
KR20050036852A (ko) * 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
MXPA04003535A (es) * 2001-10-15 2005-06-20 Immunomedics Inc Proteinas de enlace para objetivos directos.
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
AU2003215365A1 (en) * 2002-02-21 2003-09-09 Duke University Treatment methods using anti-cd22 antibodies
EP1510943A4 (en) * 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
US7098016B2 (en) * 2002-06-14 2006-08-29 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
JPWO2004003198A1 (ja) * 2002-06-27 2005-10-27 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法、および治療のための薬剤
WO2004033499A1 (ja) 2002-10-11 2004-04-22 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2004087763A1 (ja) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Ｃｄ２２に対する改変抗体およびその利用
ES2381841T3 (es) * 2003-07-11 2012-06-01 Oncotherapy Science, Inc. Método para tratar el sarcoma sinovial
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
AU2004297109A1 (en) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
EP1757686A4 (en) 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd INDUCER OF CELL DEATH
JP4700970B2 (ja) 2005-01-14 2011-06-15 鬼怒川ゴム工業株式会社 ドアグラスランの取付構造
JP5057967B2 (ja) * 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP1900814A4 (en) * 2005-06-10 2010-07-21 Chugai Pharmaceutical Co Ltd SCREED SC (FV) 2-MUTANTE
US7827400B2 (en) * 2005-07-28 2010-11-02 The Boeing Company Security certificate management
PE20081004A1 (es) * 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
JP5317697B2 (ja) * 2006-08-14 2013-10-16 中外製薬株式会社 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Also Published As

Publication number Publication date
KR20090119992A (ko) 2009-11-23
CA2680280A1 (en) 2008-09-18
TW200846372A (en) 2008-12-01
IL200375A0 (en) 2010-04-29
PE20081881A1 (es) 2009-02-18
WO2008111597A1 (ja) 2008-09-18
US20100092461A1 (en) 2010-04-15
AU2008225478A1 (en) 2008-09-18
CN101687034A (zh) 2010-03-31
AR066690A1 (es) 2009-09-09
EP2133093A1 (en) 2009-12-16
JPWO2008111597A1 (ja) 2010-06-24
CL2008000719A1 (es) 2008-09-05
BRPI0808731A2 (pt) 2013-08-06

Similar Documents

Publication Publication Date Title
MX2009009700A (es) Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
CY1121646T1 (el) Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
EP4303236A3 (en) Cytotoxicity-inducing therapeutic agent
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
WO2010036918A3 (en) Intracellular dna receptor
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
WO2010085665A3 (en) Targeted delivery system
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
EP4083071A3 (en) Combination therapy with an anti-cd19 antibody and a purine analog
WO2010145849A3 (en) Drug delivery systems
ATE553189T1 (de) Immunokinasen
MX2013014933A (es) Terapia de combinacion con un anticuerpo anti-cd19 y una mostaza de nitrogeno.
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
AU317011S (en) Tractor
WO2006039343A3 (en) Emmprin antagonists and uses thereof
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
IL200517A0 (en) Agent for use in the case of fructose intolerance
WO2009154714A3 (en) Intravenous bandage with port pocket
WO2014062228A8 (en) An improved nanovector based drug delivery system for overcoming drug resistance
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
WO2008121028A3 (en) Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer
WO2012061395A3 (en) Cytotoxic agents against cancer cells and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal